TP53 and colorectal carcinoma: Finally, we show that pharmacological inhibition of SQLE suppresses CRC cell viability, which is more pronounced in p53-deficient CRC cells with high c-MYC expression, suggesting that SQLE represents a vulnerability of CRCs with p53 inactivation and elevated c-MYC activity.